Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2020 | Phase III study of plinabulin and pegfilgrastim for chemotherapy-induced neutropenia

Douglas Blayney, MD, Stanford Cancer Institute, Stanford, CA, discusses the results of a randomized, Phase III study evaluating plinabulin and pegfilgrastim versus pegfilgrastim monotherapy for the prevention of chemotherapy-induced neutropenia after docetaxel, adriamycin, and cyclophosphamide chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.